Paul Mannion elected as CMA President
Complementary Medicines Australia (CMA) has welcomed the election of Paul Mannion, Director of Product Innovation at Blackmores, to the presidency of the CMA Board.
Mr Carl Gibson, CEO of CMA said: “We are delighted to welcome Paul into his role as President of CMA. Paul’s knowledge of the industry is invaluable, as is his vision for the development of the complementary medicines sector and his deep understanding of the intersection between modern science and traditional medicine.”
“Paul joined the CMA Board in 2012 and, with a background in product development, regulatory and government affairs, clinical research, medical education and strategic planning, brings a broad range of commercial experience to the table”, said Mr Gibson. CMA is also pleased to announce that past President, Mr Dusko Pejnovic, CEO of Lipa Pharmaceuticals, has been appointed to the role of Vice President.
“We thank Dusko for his valuable contribution to the industry during his tenure as President and are delighted that he will remain an active member of the Board.”
“Our latest industry audit shows that we are now a $4.9 billion industry in Australia. Our exports go from strength to strength, and there is a growing acceptance of the benefits of our quality therapeutic complementary medicines as an element of preventive health.”
“CMA is excited about taking the industry forward, continuing in our work to ensure that consumers have access to locally manufactured, innovative and high-quality products,” said Mr Gibson.
Taken from CMA Media Release 3 October 2018
.png)